Guidance on the use of imatinib for chronic myeloid leukaemia

Leukaemia (chronic myeloid) - imatinib: review decision-October 2014 information

Leukaemia (chronic myeloid) - imatinib: appendix a-GE decision paper-October 2014 (PDF 111 KB)

TA70 Leukaemia (chronic myeloid) - imatinib: review proposal August 2014 information

TA70 Leukaemia (chronic myeloid) - imatinib: appendix a - provisional matrix of stakeholders (PDF 104 KB)

TA70 Leukaemia (chronic myeloid) - imatinib: appendix b - proposal paper presented to the Institute's Guidance Executive (PDF 571 KB)

Review decision: July 2009 information

Review decision - July 2009 appendix 1: proposal comment summary table (PDF 43 KB)

Review proposal: May 2009 information

Review proposal: May 2009, Appendix A - provisional matrix (PDF 47 KB)

Review proposal information

Leukaemia (chronic myeloid) - imatinib: review decision information

Final Appraisal Determination: Imatinib for chronic myeloid leukaemia information

Final Appraisal Determination: Imatinib for chronic myeloid leukaemia (PDF 151 KB)

Appraisal Consultation Document: Imatinib for chronic myeloid leukaemia information

Scope: Imatinib for Chronic Myeloid Leukaemia (first line therapy) information

Protocol: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase (PDF 141 KB)

Assessment Report: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase (PDF 1.17 MB)